1. Hauptnavigation
  2. Navigation des Hauptbereiches
  3. Inhalt der Seite

Press Officer and Head of Press and Public Relations

Dr. Stefanie Seltmann
Dr. Stefanie Seltmann

Im Neuenheimer Feld 280
69120 Heidelberg

Phone: +49 6221 422854
Fax: +49 6221 422968

E-Mail: s.seltmann@dkfz.de
or presse@dkfz.de

Recent Press Releases

No. 47 | 09. October 2014 | by Sok/München

New method can predict side effects of anticancer drugs

New method can predict side effects of anticancer drugs

Every new anticancer drug can improve patients’ chances of survival. In some cases, however, these drugs can cause severe adverse side effects through mechanisms that are often unclear. An international team of researchers from Munich, Heidelberg, Sweden and Singapore has now succeeded in developing a new method that helps explain and even predict side effects that occur at cellular level.

No. 46 | 08. October 2014 | by Sel

Nobel Prize winner at the Max Planck Institute for Biophysical Chemistry in Göttingen and the German Cancer Research Center: Nobel Prize in Chemistry awarded to Stefan Hell

Nobel Prize winner at the Max Planck Institute for Biophysical Chemistry in Göttingen and the German Cancer Research Center: Nobel Prize in Chemistry awarded to Stefan Hell

For the second time a researcher at the DKFZ has been awarded the highest distinction in science: Professor Stefan Hell, director of the Max-Planck Institute for Biophysical Chemistry in Göttingen and department head at the DKFZ, has been awarded this year´s Nobel Prize in Chemistry for his pioneering work in the field of ultra high resolution fluorescence microscopy. This follows the 2008 Nobel Prize in Medicine for Harald zur Hausen.

No. 44b | 01. October 2014 | by Sok/Düsseldorf/LDC

DKTK partner site Essen/Düsseldorf starts new cooperation with industry

DKTK partner site Essen/Düsseldorf starts new cooperation with industry

Joint Press Release of the German Cancer Consortium and the Lead Discovery Center
The Lead Discovery Center GmbH (LDC), a renowned translational research organization, and the Helmholtz Association, Germany’s biggest scientific organization, will be collaborating more closely in future. An initial pilot project in cooperation with Professor Schulte’s research group at the DKTK partner site Essen/Dusseldorf has just been launched. Together with the LDC, they will be developing a novel cancer therapy approach with the aim of identifying new drug candidates for the treatment of neuroblastoma and other cancer types.

Audio (in German only)
einblick (in German only)
Publications
Videos (in German only)
last update: 16/10/2013 back to top